Research Analysts Set Expectations for TESARO Inc’s FY2022 Earnings (TSRO)
TESARO Inc (NASDAQ:TSRO) – Research analysts at SunTrust Banks issued their FY2022 earnings estimates for shares of TESARO in a report released on Thursday. SunTrust Banks analyst P. Lawson anticipates that the biopharmaceutical company will post earnings per share of $9.96 for the year. SunTrust Banks has a “Buy” rating and a $160.00 price objective on the stock.
TESARO (NASDAQ:TSRO) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.16) by $0.69. The firm had revenue of $142.77 million for the quarter, compared to analyst estimates of $130.57 million. TESARO had a negative net margin of 251.22% and a negative return on equity of 93.39%. The company’s revenue for the quarter was up 740.3% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.72) earnings per share.
TESARO (NASDAQ TSRO) traded down $2.07 during trading hours on Monday, reaching $69.59. 1,747,500 shares of the company’s stock were exchanged, compared to its average volume of 1,093,056. The firm has a market capitalization of $3,780.00, a price-to-earnings ratio of -8.26 and a beta of 1.51. TESARO has a 52-week low of $69.38 and a 52-week high of $192.94. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.35 and a current ratio of 4.73.
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Hanseatic Management Services Inc. increased its stake in TESARO by 0.3% in the second quarter. Hanseatic Management Services Inc. now owns 5,936 shares of the biopharmaceutical company’s stock valued at $830,000 after purchasing an additional 15 shares in the last quarter. Stephens Inc. AR increased its stake in TESARO by 6.5% in the second quarter. Stephens Inc. AR now owns 1,874 shares of the biopharmaceutical company’s stock valued at $262,000 after purchasing an additional 115 shares in the last quarter. Cornerstone Capital Management Holdings LLC. increased its stake in TESARO by 1.1% in the second quarter. Cornerstone Capital Management Holdings LLC. now owns 12,092 shares of the biopharmaceutical company’s stock valued at $1,690,000 after purchasing an additional 136 shares in the last quarter. KBC Group NV increased its stake in TESARO by 10.9% in the third quarter. KBC Group NV now owns 5,606 shares of the biopharmaceutical company’s stock valued at $724,000 after purchasing an additional 553 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System increased its stake in TESARO by 1.2% in the third quarter. State Board of Administration of Florida Retirement System now owns 49,054 shares of the biopharmaceutical company’s stock valued at $6,333,000 after purchasing an additional 570 shares in the last quarter.
In related news, SVP Martin H. Jr. Huber sold 829 shares of the business’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $85.24, for a total transaction of $70,663.96. Following the completion of the sale, the senior vice president now directly owns 8,101 shares of the company’s stock, valued at $690,529.24. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 34.60% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was posted by American Banking News and is the property of of American Banking News. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.americanbankingnews.com/2018/01/15/research-analysts-set-expectations-for-tesaro-incs-fy2022-earnings-tsro.html.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.